A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors

@inproceedings{Chatterjee2016AHA,
  title={A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors},
  author={Samit Chatterjee and Wojciech G. Lesniak and Matthew Gabrielson and Ala Lisok and Bryan Wharram and Polina Sysa-Shah and Babak Behnam Azad and Martin G. Pomper and Sridhar Nimmagadda},
  booktitle={Oncotarget},
  year={2016}
}
Antibodies targeting the PD-1/PD-L1 immune checkpoint lead to tumor regression and improved survival in several cancers. PD-L1 expression in tumors may be predictive of response to checkpoint blockade therapy. Because tissue samples might not always be available to guide therapy, we developed and evaluated a humanized antibody for non-invasive imaging of PD-L1 expression in tumors. Radiolabeled [111In]PD-L1-mAb and near-infrared dye conjugated NIR-PD-L1-mAb imaging agents were developed using… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 39 references

Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer

  • N Rizvi, JR Brahmer, o Sai-Hong Ignatious, NH S, S. Khleif
  • (NSCLC). 2015 ASCO Annual Meeting (Journal of…
  • 2015
Highly Influential
12 Excerpts

Similar Papers

Loading similar papers…